Inozyme Pharma Ownership
| INZY Stock | USD 1.37 0.02 1.48% |
Shares in Circulation | First Issued 2019-06-30 | Previous Quarter 62 M | Current Value 63 M | Avarage Shares Outstanding 31.3 M | Quarterly Volatility 21.4 M |
Inozyme |
Inozyme Stock Ownership Analysis
About 93.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.06. Some equities with similar Price to Book (P/B) outperform the market in the long run. Inozyme Pharma recorded a loss per share of 1.55. The entity had not issued any dividends in recent years. Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. Inozyme Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 50 people. To learn more about Inozyme Pharma call Douglas Treco at 857 330 4340 or check out https://www.inozyme.com.Besides selling stocks to institutional investors, Inozyme Pharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Inozyme Pharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Inozyme Pharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Inozyme Pharma Quarterly Liabilities And Stockholders Equity |
|
Only 1.3% of Inozyme Pharma are currently held by insiders. Unlike Inozyme Pharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Inozyme Pharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Inozyme Pharma's insider trades
Inozyme Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Inozyme Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inozyme Pharma backward and forwards among themselves. Inozyme Pharma's institutional investor refers to the entity that pools money to purchase Inozyme Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2024-09-30 | 1.7 M | Samsara Biocapital, Llc | 2024-09-30 | 1.6 M | Saturn V Capital Management Llc | 2024-09-30 | 1.4 M | Sphera Funds Management Ltd. | 2024-09-30 | 1.2 M | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | Blue Owl Capital Holdings Lp | 2024-09-30 | 1.1 M | State Street Corp | 2024-09-30 | 1.1 M | Woodline Partners Lp | 2024-09-30 | 1 M | Goldman Sachs Group Inc | 2024-09-30 | 447.3 K | Adage Capital Partners Gp Llc | 2024-09-30 | 5.7 M | Pivotal Bioventure Partners Investment Advisor Llc | 2024-09-30 | 4.5 M |
Inozyme Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inozyme Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inozyme Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inozyme Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Inozyme Pharma Outstanding Bonds
Inozyme Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Inozyme Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Inozyme bonds can be classified according to their maturity, which is the date when Inozyme Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US457985AM13 Corp BondUS457985AM13 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.